Our Company

Scientific Advisors

TALLC has built an expert team of pre-clinical and clinical scientists to guide development of TA-A001 and TALLC’s pipeline products.

Prof. Robert Sneyd

Chairman of the Scientific Advisory Committee

Professor Sneyd’s research interests focus on drugs, pharmacology and pharmacokinetics with related projects based on signal processing. Having worked in the pharmaceutical industry he has a special interest in drug development, especially in Intravenous Anaesthesia. He now works as Dean of the Plymouth University Peninsula Schools of Medicine and Dentistry in Plymouth, UK and leads programmes in medicine and dentistry.

Professor Rob Sneyd is also an experienced board member in both executive and non-executive roles. He has long experience of establishing new organisations and steering them through changing circumstances and an impressive track record of delivery.

Prof. Melanie Kelly

Department Ophthalmology & Visual Sciences, Dalhousie University

Dr. Kelly’s primary research expertise is molecular and functional pharmacology with a special interest in translational pharmacology and drug development in the cannabis/cannabinoid space. Dr. Kelly’s lab has research expertise in ocular and central nervous system pharmacology and therapeutics and examines use of drugs that target the endocannabinoid system for neurodegenerative disease and pain and inflammation.

Prof. Yoram Shir

Professor of Anaesthesia: Edwards Chair in Clinical Pain

Following training in anesthesiology and pain medicine at Johns Hopkins Hospital, Dr. Shir served as Director of the Pain Relief Unit at Hadassah University Hospital in Jerusalem. In addition to research, his clinical responsibilities include serving as Director of the Alan Edwards Pain Management Unit, McGill University Health Centre, in Montreal. Dr. Shir’s research focuses on means to improve therapeutic outcome of patients with chronic non-cancerous and cancer pain.

Prof. Langis Michaud

Dean University of Montreal School of Optometry

Langis is a Fellow of the American Academy of Optometry (Diplomate), the British Contact Lens Association, the Scleral Lens Education Society and of the European Academy of Optometry. His main research interests are myopia control, scleral contact lenses, keratoneuralgia and anterior segment irregularities including keratoconus. He has published numerous articles in peer-reviewed journals and is a regular speaker at major optometric and ophthalmology meetings around the world.

Dr. Jianmin Duan
Jianmin worked for 21 years in drug discovery and development at Boehringer Ingelheim,
overseeing all preclinical drug development programs of the company.
As an experienced team leader with more than 20 years of track records in drug absorption,
distribution, metabolism, excretion, pharmacokinetics and pharmacology, his skills cover
three main areas of expertise:
-General and project-specific strategy planning and prioritization: identifying the critical
PK/PD parameters for effective optimizations;
-Experimental design, data analysis, and interpretations on ADME/PK and pharmacology
studies: ensuring the most efficient use of resources to achieve the highest quality data
within the best timeline, such as best dosage selections, sample time, and statistical power.
– Identification of key issues and providing solutions on how to improve oral bioavailability,
half-life, IVIVC and human PK/PD/Tox predictions, efficient selection and implementation
of PK and PK/PD models, and the application of software to guide drug evolution,
candidate selection, toxicology evaluations and clinical trials, as well as staff training.

Management Team

Board of Directors

CONTACT US

Phone: 514 883 3447

Email: info@tallcinc.com

NEWS

TALLC issues new Corporate Presentation

Dr. Damon Smith at Biotech Show Case

TALLC at the Ophthalmology Innovation Summit

TALLC Corporation Announces Grant of New SmartCelle Patent for Enhanced Ocular Delivery of TA-A001

Tetra Bio-Pharma and Altus Formulation Form New Company “TALLC” to Exploit TA-A001

TALLC to Present at ChinaBio

See our updated presentation describing TA-A001 for neovascular disease, wound healing and new ocular bio-distribution data
https://informaconnect.com/chinabio-partnering/

Load More...
TALLC Innovation in Vision

© TALLC Inc. 2020